Effect of argatroban, a selective thrombin inhibitor, on the levels of endothelin-1, thrombomodulin, coagulation and fibrinolysis markers.

DOI 26 References

Bibliographic Information

Other Title
  • Ｅｎｄｏｔｈｅｌｉｎ‐１，ｔｈｒｏｍｂｏｍｏｄｕｌｉｎ動態および凝血系に対する選択的トロンビン抑制剤の影響について　脳血栓症急性期における検討
  • 脳血栓症急性期における検討

Search this article

Description

Endothelin-1 (ET-1) exerts powerful vasoconstrictuve and blood pressure elevating effects through endothelial cells. Plasma thrombomodulin (TM) is an endothelial cell marker which may reflect endothelial damage. Argatroban, a synthetic selective thrombin inhibitor, has been shown to exhibit a potent anti-thrombotic effect in experimental thrombosis models using animals. However, the influences of argatroban on the levels of ET-1 and TM, and markers of coagulation and fibrinolysis have not been examined precisely.<BR>In this study, we investigated the effects of argatroban using 16 patients with acute cerebral thrombosis. The plasma level of ET-1 in the argatroban group was significantly decreased from 4.5 ± 1.7 pg/ml to 2.9 ± 1.4 pg/ml on day 1 as compared to that in the control group. On the other hand, no significant changes in TM were noted in both the argatroban group and control group. The plasma level of TM in the cerebral thrombosis patients was significant higher than the TM level in age-matched controls. The level of D-dimer in the argatroban group revealed lower values throughout the study as compared to those in the controls. It is concluded that argatroban may reduce the induction of ET-1 from the endothelium and may have a therapeutic effect on human thrombotic disease through selective and potent inhibition of thrombin.

Journal

References(26)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top